PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial

PharmAla Biotech Holdings Inc. MDXXF, a Canadian company specializing in MDMA research and development, announced its selection as a supplier for a clinical trial at the University of Texas, San Antonio. The trial will focus on testing a novel dosage form of PharmAla's proprietary LaNeo MDMA.

This development follows a grant application by the research team, which will explore the potential of the new dosage form in an investigator-led human clinical trial. PharmAla will provide the new formulation in addition to its existing 40mg MDMA capsules, being used in Canada and Australia for assisted therapy.

Nicholas Kadysh, CEO of PharmAla Biotech, expressed enthusiasm about partnering with the researchers. "We're excited to support this trial by not only providing our existing dosage forms but also working on new, innovative ways to deliver MDMA. We always welcome opportunities to explore different dose models."

Patent Publication Milestones

PharmAla has also announced the recent publication of a patent application as part of its intellectual property strategy. The patent, filed with the U.S. Patent and Trademark Office, covers potential uses of PharmAla's APA-01, a novel molecular entity. This follows the approval of the company’s initial APA-01 patent earlier this year (US Patent #12,042,428). Dr. Harpreet Kaur, VP of Research at PharmAla, highlighted the support from their partners at Intellectual Property Ontario (IPON). "Their backing through non-dilutive grants continues to be a significant motivator as we work to keep this valuable intellectual property in Canada."

Cover image made with AI